Zai Lab Ltd (ZLAB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.07B
Last updated: Nov 17, 2026 at 4:10 PM ET
Zai Lab Ltd (ZLAB) Statistics
Zai Lab (ZLAB) has a market cap of $3.07B and an enterprise value of $2.77B. It kept -44.91% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 9.68% below the market cap, as cash exceeds debt.
| Market Cap | $3.07B |
|---|---|
| Enterprise Value | $2.77B |
| Latest price (Nov 17, 2026) | $23.53 |
Key Dates
| Last Earnings Date | Nov 5, 2026 |
|---|---|
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 6.0x and 4.7x. Its year-end P/S ranged from 4.2x to 407.9x from 2021 to 2025.
| P/S Ratio | 6.0x |
|---|---|
| Forward P/S | 7.0x |
| P/B Ratio | 4.7x |
| P/TBV Ratio | 5.5x |
Price Statistics
The stock is up 8.18% over 52 weeks and trades 4.04% below its 50-day average.
| Beta (1Y) | 1.01 |
|---|---|
| 52-Week Change | +8.18% |
| 1-Month Change | -2.20% |
| 3-Month Change | -11.94% |
| 6-Month Change | +28.09% |
| 5-Year Change | -78.86% |
| Total Return (1Y) | +8.18% |
| Total Return (3Y CAGR) | -5.14% |
| Total Return (5Y CAGR) | -22.85% |
| Return vs SPY (1Y) | +3.33% |
| Max Drawdown (1Y) | -34.73% |
| Max Drawdown (3Y) | -62.12% |
| Sharpe Ratio (1Y) | 0.27 |
| Correlation with SPY (1Y) | 0.27 |
| 50-Day Average | $24.52 |
| 200-Day Average | $21.37 |
| 52-Week Range | $15.96 to $29.02 |
| RSI (14 Days) | 46.3 |
| Average Volume (20 Days) | 1.33M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.04x current liabilities, and total debt is 0.45x shareholder equity.
| Current Ratio | 2.04x |
|---|---|
| Quick Ratio | 1.84x |
| Debt / Equity | 0.45x |
| Interest Coverage | -31.91x |
Returns and Efficiency
Return on invested capital is -23.58% over the last 12 months, against a 5-year average of -34.41%.
| Return on Equity (ROE) | -35.22% |
|---|---|
| Return on Assets (ROA) | -19.38% |
| Return on Invested Capital (ROIC) | -23.58% |
| Return on Capital Employed (ROCE) | -32.79% |
| ROE (5Y Average) | -38.12% |
| ROA (5Y Average) | -29.81% |
| ROIC (5Y Average) | -34.41% |
| Asset Turnover | 0.40x |
| Inventory Turnover | 2.27x |
| Receivables Turnover | 5.95x |
| Cash Conversion Cycle | -12 days |
Scores
ZLAB has an Altman Z-Score of -0.04, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -0.04 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $441.73M over the last 12 months is up 0.02% from the 12 months before.
| Revenue | $441.73M |
|---|---|
| Revenue Growth (YoY) | +0.02% |
| Gross Profit | $241.59M |
| Operating Income | -$278.15M |
| Pretax Income | -$202.77M |
| Net Income | -$198.39M |
| EBITDA | -$184.57M |
| EBIT | -$196.60M |
| Reported EPS (TTM) | -$1.79 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 55.22% of the $1.02B in total assets.
| Cash and Equivalents | $549.66M |
|---|---|
| Total Debt | $252.37M |
| Net Cash | $297.29M |
| Working Capital | $440.15M |
| Shareholder Equity | $563.28M |
| Tangible Book Value | $477.98M |
| Total Assets | $1.02B |
| Total Liabilities | $460.62M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $26.00M of capital spending, operating cash flow left -$185.20M of free cash flow.
| Operating Cash Flow | -$159.21M |
|---|---|
| Capital Expenditures | $26.00M |
| Free Cash Flow | -$185.20M |
| FCF Per Share | -$1.48 |
| Depreciation and Amortization | $17.85M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -62.97%.
| Gross Margin | 54.69% |
|---|---|
| Operating Margin | -62.97% |
| Pretax Margin | -45.90% |
| Net Margin | -44.91% |
| EBITDA Margin | -41.78% |
| EBIT Margin | -44.51% |
| FCF Margin | -41.93% |
| Gross Margin (5Y Average) | 62.97% |
Growth
Revenue grew 28.86% a year over 3 years.
| Revenue Growth (3Y CAGR) | +28.86% |
|---|---|
| Revenue Growth (5Y CAGR) | +56.54% |
Dividends and Yields
ZLAB does not pay a dividend. Its free cash flow yield is -7.01%.
| FCF Yield | -7.01% |
|---|---|
| Shareholder Yield | 0.00% |
Peer Position
Against 11 similar companies, ZLAB has the 8th highest P/S.
P/S RatioPeer median 13.1x
ROICPeer median -28.99%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +29.42%
| P/S Ratio | 6.0x vs 13.1x median |
|---|---|
| ROIC | -23.58% vs -28.99% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +0.02% vs +29.42% median |
Analyst Forecast
Consensus estimates put revenue growth at 21.63% a year over the next 5 fiscal years.
| Revenue Growth Forecast (5Y CAGR) | +21.63% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ZLAB
What is ZLAB's market cap?
Zai Lab has a market cap of $3.07B. Its enterprise value, which adds debt and subtracts cash, is $2.77B.
How many shares of ZLAB are outstanding?
Zai Lab has 112.34M shares outstanding. The count is up 1.94% from a year earlier.
Does ZLAB pay a dividend?
No. Zai Lab does not pay a dividend.
How much debt does ZLAB have?
Zai Lab has $252.37M of total debt and $549.66M of cash and equivalents, a net cash position of $297.29M.
ZLAB pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors